Beacon Medical Interchange

beaconmedic.com

 

Beacon Medical Interchange
Avatar

New PARP Inhibitor Abiraterone Combo in Met Prostate Cancer: ASCO 2018 GU Highlights

By Beacon Medical Interchange FEATURING Daniel Goldstein
By Beacon Medical Interchange FEATURING Daniel Goldstein
665 views
November 2, 2018
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the ...
read more ↘
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Prostate
01:35
Beacon Medical Interchange

Adj. Docetaxel for Int. or High Risk Prostate Cancer After Rad: ASCO…

Feat. D. Goldstein
02:47
Beacon Medical Interchange

What is Positive Predictive Value of PET PSMA in Prostate Cancer? AS…

Feat. D. Goldstein
03:03
Beacon Medical Interchange

New PARP Inhibitor Abiraterone Combo in Met Prostate Cancer: ASCO 20…

Feat. D. Goldstein
02:03
Beacon Medical Interchange

PROSTVAC Vaccine Therapy for Advanced Prostate Cancer? ASCO 2018 GU …

Feat. D. Goldstein
01:09
Beacon Medical Interchange

Is More Better with Radium-223 for Metastatic Prostate Cancer? ASCO …

Feat. D. Goldstein
02:18
Beacon Medical Interchange

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: ASCO…

Feat. D. Goldstein